Baxa releases DoseEdge Pharmacy Workflow Management System

NewsGuard 100/100 Score

Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations and increase patient safety, today announced the release of new features for its DoseEdge Pharmacy Workflow Management System.  The upgrades extend DoseEdge capabilities to include mobile dose tracking, more pharmacist verification options and enhanced dose status monitoring.  

Along with a range of configurable options that add new security parameters to the verification process, DoseEdge users also gain access to extended scanning capabilities.  This enables new tracking options for scan-tracking doses outside the pharmacy.  An easy-to-read, programmable Status Board displays key dose information to appropriate health-system staff, enabling pharmacists and technicians to spend more time focusing on patient safety and less time chasing lost doses.

"Now, health-system pharmacists can use a better, more robust, integrated system to safely and efficiently prepare a broader range of doses, including oral doses," said Dennis Tribble, PharmD, Baxa Chief Pharmacy Officer.  "Our team of pharmacy experts focused on key features that will give DoseEdge users further confidence during the IV and oral medication preparation processes, as well as flexible tools that will improve both verification and tracking."

Source:

Baxa Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity